Faculty profile
Terry Hawrysh
Back to facultyThis profile is built from public research funding records (CIHR, NSERC and SSHRC). We have not imported them from a University of British Columbia directory, so their publications, courses and email address may be missing. Find their university profile.
Research
Latest funding
- $3,051,528
A Phase I trial of single domain antibody-based CD22 chimeric antigen receptor (CAR)-T cells for the treatment of relapsed/refractory CD22+ B-cell acute lymphoblastic leukemia
CIHR · 2022 · Principal investigator
- $762,882
A Phase I trial of single domain antibody-based CD22 chimeric antigen receptor (CAR)-T cells for the treatment of relapsed/refractory CD22+ B-cell acute lymphoblastic leukemia
CIHR · 2022 · Principal investigator
A Phase I trial of single domain antibody-based CD22 chimeric antigen receptor (CAR)-T cells for the treatment of relapsed/refractory CD22+ B-cell acute lymphoblastic leukemia
Principal investigators: Hay, Kevin A; Hawrysh, Terry A; Kekre, Natasha; Krueger, Joerg; Li, Amanda; Szwajcer, David
Keywords: Adoptive Immunotherapy; B-Cell Acute Lymphoblastic Leukemia; Cd22; Chimeric Antigen Receptor T Cells (Car-T)
A Phase I trial of single domain antibody-based CD22 chimeric antigen receptor (CAR)-T cells for the treatment of relapsed/refractory CD22+ B-cell acute lymphoblastic leukemia
Principal investigators: Hay, Kevin A; Hawrysh, Terry A; Kekre, Natasha; Krueger, Joerg; Li, Amanda; Szwajcer, David
Keywords: Adoptive Immunotherapy; B-Cell Acute Lymphoblastic Leukemia; Cd22; Chimeric Antigen Receptor T Cells (Car-T)
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.